Complex hemostatic changes in uremic patients are characterized by platelet distress and prolonged bleeding time. Dialysis corrects platelet function and improves the bleeding time but introduces a tendency to thrombophilia. The uremic patient is thus an excellent model for the evaluation of hemostatic drugs. VUEFFE (VF) is a new hemostatic agent which reduces bleeding time without modifying clotting parameters. Changes in hemostasis and coagulation were studied in 42 hemorrhagic uremic subjects in dialysis or on conservative management. The patients were divided into two groups, one of which was given oral VF and the other oral placebo. 84% of those receiving VF ceased bleeding within 15 days (compared to 25% for placebo) and there was a singificant reduction in bleeding time. The drug can be given orally or parenterally, is well tolerated and without side effects, making it suitable for administration to hemorrhagic uremic patients.